Chandran et al. identified syndecan-1 (SDC1) as a plasma EV constituent that discriminates between high-grade glioblastoma (World Health Organization (WHO) grade IV), low-grade glioma (LGG, WHO grade II), and plasma EV SDC1 correlated with SDC1 protein expression in matched patient tumors, for which the level of plasma EV SDC1 was decreased after surgery [59]. The gene discussed is SDC1; the disease is glioma.